



SHUKRA
PHARMACEUTICALS LTD.

29th April, 2024

To
The General Manager-Listing
Corporate Relationship Department
BSE Limited, Ground Floor,
P.J. Towers, Dalal Street, Mumbai

Scrip Code: -524632

Dear Sir/Madam,

Sub: Compliance with the Regulation 76 of SEBI (DP) Regulations, 2018

With reference to above, please find the Reconciliation of Share Capital Audit Report for the Quarter ended on March 31, 2025 in compliance in with Reg. 76 of SEBI (DP) Regulations, 2018.

Please take the same on your record and oblige.

Thanking you.
Yours faithfully,

For Shukra Pharmaceuticals Limited

bpa
Bhoomi Patel
Director
DIN:0836893



Encl.: a/a

CIN : L24231GJ1993PLC019079



To,
The Board of Directors
Shukra Pharmaceuticals Limited
3rd floor, Dev House, Opp. WIAA,
Judges Bungalows Road, Bodakdev,
Ahmedabad, Gujarat, 380054

Dear Sir/Madam,

We have examined the Register of Members, beneficiary details furnished by the Depositories and other records /documents maintained by **Shukra Pharmaceuticals Limited** (hereinafter referred to as the “**Company**”) and its Registrars and Share Transfer Agents, **Purva Sharegistry (India) Pvt. Ltd.** for issuing this certificate, in respect of Reconciliation of Share Capital Audit as per SEBI Cir. D&CC/FITTC/CIR-16/2002 dated December 31, 2002 and SEBI Circular No. CIR/MRD/DP/ 30/2010 dated September 06, 2010 and regulation 76 of the SEBI (Depositories and Participants) Regulations, 2018. To the best of our knowledge and according to the information and explanations given to us, **We Certifying the Following:**

RECONCILIATION OF SHARE CAPITAL AUDIT REPORT

S.N.	Particulars	Details	
1	For Quarter Ended	March 31, 2024	
2	ISIN	For fully paid equity shares: INE551C01044	
3	Face Value	₹01/- (Rupees Ten Only)	
4	Name of the Company	Shukra Pharmaceuticals Limited	
5	Registered Office Address	3 rd Floor, Dev House, Opp. WIAA Office, Judges Bungalows Road, Bodakdev, Ahmedabad– 380054	
6	Correspondence Address	3 rd Floor, Dev House, Opp. WIAA Office, Judges Bungalows Road, Bodakdev, Ahmedabad– 380054	
7	Telephone & Fax Nos.	Phone No: 079-48000430	
8	Email Address	info@shukrapharmaceuticals.com	
9	Names of the Stock Exchanges where the company's securities are listed:	BSE Limited, Mumbai	
10	Issued Capital	No. of Shares	% of Total Issued Cap
		43,78,79440	100.00
11	Listed Capital (Exchange-wise) (As per Company records)	No. of Shares	% of Total Issued Cap
		43,78,79,440	100.00
12	Held in dematerialized form in CDSL	No. of Shares	% of Total Issued Cap
		32,70,06,570	74.68
13	Held in dematerialized form in NSDL	No. of Shares	% of Total Issued Cap
		11,00,00,980	25.12



14	Physical	<table><tr><th>No. of Shares</th><th>% of Total Issued Cap</th></tr><tr><td>87,1890</td><td>0.20</td></tr></table>					No. of Shares	% of Total Issued Cap	87,1890	0.20
No. of Shares	% of Total Issued Cap									
87,1890	0.20									
15	Total No. of shares (12+13+14)	43,78,79,440 Shares								
16	Reasons for difference if any, between (10&11), (10&15), (11&15):	NIL								
17	Certifying the details of changes in share capital during the quarter under consideration as per Table below:	NIL								
Particulars***		No. of shares	Applied / Not Applied for listing	Listed on Stock Exchanges (Specify Names)	Whether intimated to CDSL	whether intimated to NSDL	In-prin. approval pending for SE (Specify Names)			
Sub division/Split		394091496	Yes	BSE Limited	Yes	Yes	No			
The Company has sub-divided the Equity Shares of the Company such that every 1(One) Equity Share having nominal/face value of Rs. 10/- (Rupees Ten Only) each be sub-divided into 10 (Ten) Equity Shares having nominal/face value of Rs. 1/- (Rupees One Only) each.										
18	Register of Members is updated (Yes / No), If not updated, up to which date?			YES						
19	Reference of previous quarter with regards to excess dematerialized shares, if any.			NIL						
20	Has the company resolved the matter mentioned in point no.19 above in the current quarter? If not, reason, Why?			N.A.						
21	Mentioned the total no. of requests, if any, confirmed after 21 days and the total no. of requests pending beyond 21 days with the reasons for delay			NIL						
22	Name, Telephone & Fax No. of the Compliance Officer of the Co.			Ms. Arpita Kabra, Company Secretary Office Address: 3 rd Floor, Dev House, Opp. WIAA Office, Judges Bungalows Road, Bodakdev,						



		Ahmedabad– 380054 Phone: 9529291107
23	Name, Address, Tel. & Fax No., Regn. no. of the Practising Company Secretary	Mrs. Rupal Patel, Practising Company Secretary FCS No. 6275, COP NO. 3803, Address: 303, Prasad Tower, Opp. Jain Derasar, Nehrunagar Char Rasta, Ahmedabad, Gujarat- 380015. Tel. No. (M) 9825507376
24	Appointment of Common Share Registry for Share Registry Work (if yes, name & address)	Purva Sharegistry (India) Pvt. Ltd. Unit no. 9, Shiv Shakti Ind. Esstt., J .R. Boricha Marg, Opp. Kasturba Hospital Lane, Lower Parel (E), Mumbai 400 011 Tel: 91-22-2301 6761 / 8261 Email: support@purvashare.com
25	Any other detail that the Practising Company Secretary may like to provide. (e.g. BIFR company, delisting from SE, company changed its name etc.)	The Company has sub-divided the Equity Shares of the Company such that every 1(One) Equity Share having nominal/face value of Rs. 10/- (Rupees Ten Only) each be sub-divided into 10 (Ten) Equity Shares having nominal/face value of Rs. 1/- (Rupees One Only) each.

Date: 30.04.2025

Place: Ahmedabad

Rupal Patel
Practicing Company Secretary
CP No. 3803
UDIN: F006275G000242808